AR098983A1 - Composición combinada de bromuro de glicopirronio y formoterol en solución estable presurizada para aerosol - Google Patents
Composición combinada de bromuro de glicopirronio y formoterol en solución estable presurizada para aerosolInfo
- Publication number
- AR098983A1 AR098983A1 ARP140104939A ARP140104939A AR098983A1 AR 098983 A1 AR098983 A1 AR 098983A1 AR P140104939 A ARP140104939 A AR P140104939A AR P140104939 A ARP140104939 A AR P140104939A AR 098983 A1 AR098983 A1 AR 098983A1
- Authority
- AR
- Argentina
- Prior art keywords
- range
- dosage
- salt
- pharmaceutical composition
- aerosol
- Prior art date
Links
- 239000000443 aerosol Substances 0.000 title abstract 10
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 title abstract 4
- 229960002848 formoterol Drugs 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 3
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 6
- 150000003839 salts Chemical class 0.000 abstract 6
- 239000002253 acid Substances 0.000 abstract 5
- 229910052500 inorganic mineral Inorganic materials 0.000 abstract 4
- 239000011707 mineral Substances 0.000 abstract 4
- 239000003381 stabilizer Substances 0.000 abstract 4
- 229920005549 butyl rubber Polymers 0.000 abstract 3
- 239000003246 corticosteroid Substances 0.000 abstract 3
- 239000006184 cosolvent Substances 0.000 abstract 3
- 229960002462 glycopyrronium bromide Drugs 0.000 abstract 3
- 229940071648 metered dose inhaler Drugs 0.000 abstract 3
- 239000003380 propellant Substances 0.000 abstract 3
- 239000012453 solvate Substances 0.000 abstract 3
- ANGKOCUUWGHLCE-UHFFFAOYSA-N 2-cyclopentyl-2-hydroxy-2-phenylacetic acid (1,1-dimethyl-3-pyrrolidin-1-iumyl) ester Chemical compound C1[N+](C)(C)CCC1OC(=O)C(O)(C=1C=CC=CC=1)C1CCCC1 ANGKOCUUWGHLCE-UHFFFAOYSA-N 0.000 abstract 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract 2
- 239000007857 degradation product Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- OBRNDARFFFHCGE-PERKLWIXSA-N (S,S)-formoterol fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1 OBRNDARFFFHCGE-PERKLWIXSA-N 0.000 abstract 1
- SMNDYUVBFMFKNZ-UHFFFAOYSA-N 2-furoic acid Chemical compound OC(=O)C1=CC=CO1 SMNDYUVBFMFKNZ-UHFFFAOYSA-N 0.000 abstract 1
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 abstract 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 abstract 1
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 abstract 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 abstract 1
- ANGKOCUUWGHLCE-HKUYNNGSSA-N [(3s)-1,1-dimethylpyrrolidin-1-ium-3-yl] (2r)-2-cyclopentyl-2-hydroxy-2-phenylacetate Chemical compound C1[N+](C)(C)CC[C@@H]1OC(=O)[C@](O)(C=1C=CC=CC=1)C1CCCC1 ANGKOCUUWGHLCE-HKUYNNGSSA-N 0.000 abstract 1
- 230000032683 aging Effects 0.000 abstract 1
- 229950000210 beclometasone dipropionate Drugs 0.000 abstract 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 abstract 1
- 229910052794 bromium Inorganic materials 0.000 abstract 1
- 229960004436 budesonide Drugs 0.000 abstract 1
- -1 butixooort Chemical compound 0.000 abstract 1
- 229960003728 ciclesonide Drugs 0.000 abstract 1
- 229960000676 flunisolide Drugs 0.000 abstract 1
- 229960002714 fluticasone Drugs 0.000 abstract 1
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 abstract 1
- 229960000289 fluticasone propionate Drugs 0.000 abstract 1
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 abstract 1
- 229960000193 formoterol fumarate Drugs 0.000 abstract 1
- 229960001798 loteprednol Drugs 0.000 abstract 1
- YPZVAYHNBBHPTO-MXRBDKCISA-N loteprednol Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)OCCl)[C@@H]4[C@@H]3CCC2=C1 YPZVAYHNBBHPTO-MXRBDKCISA-N 0.000 abstract 1
- 229960004584 methylprednisolone Drugs 0.000 abstract 1
- 229960002744 mometasone furoate Drugs 0.000 abstract 1
- WOFMFGQZHJDGCX-ZULDAHANSA-N mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 abstract 1
- 238000004806 packaging method and process Methods 0.000 abstract 1
- 229960004618 prednisone Drugs 0.000 abstract 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 abstract 1
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 abstract 1
- 229950004432 rofleponide Drugs 0.000 abstract 1
- IXTCZMJQGGONPY-XJAYAHQCSA-N rofleponide Chemical compound C1([C@@H](F)C2)=CC(=O)CC[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3O[C@@H](CCC)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O IXTCZMJQGGONPY-XJAYAHQCSA-N 0.000 abstract 1
- 229960005294 triamcinolone Drugs 0.000 abstract 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 abstract 1
- 229960002117 triamcinolone acetonide Drugs 0.000 abstract 1
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A61K9/124—Aerosols; Foams characterised by the propellant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
- A61M15/0021—Mouthpieces therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0065—Inhalators with dosage or measuring devices
- A61M15/0068—Indicating or counting the number of dispensed doses or of remaining doses
- A61M15/007—Mechanical counters
- A61M15/0071—Mechanical counters having a display or indicator
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0086—Inhalation chambers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M39/00—Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
- A61M39/22—Valves or arrangement of valves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D83/00—Containers or packages with special means for dispensing contents
- B65D83/14—Containers for dispensing liquid or semi-liquid contents by internal gaseous pressure, i.e. aerosol containers comprising propellant
- B65D83/141—Containers for dispensing liquid or semi-liquid contents by internal gaseous pressure, i.e. aerosol containers comprising propellant specially adapted for specific contents or propellants
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D83/00—Containers or packages with special means for dispensing contents
- B65D83/14—Containers for dispensing liquid or semi-liquid contents by internal gaseous pressure, i.e. aerosol containers comprising propellant
- B65D83/44—Valves specially adapted for the discharge of contents; Regulating devices
- B65D83/52—Metering valves; Metering devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M39/00—Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
- A61M39/22—Valves or arrangement of valves
- A61M2039/226—Spindles or actuating means
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Dispersion Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pain & Pain Management (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mechanical Engineering (AREA)
- Otolaryngology (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Cosmetics (AREA)
Abstract
Reivindicación 1: Una composición farmacéutica en solución para aerosol para utilizar en un inhalador presurizado de dosis medida caracterizada porque comprende: (a) bromuro de glicopirronio con una dosificación dentro del rango entre 5 y 26 mg por accionamiento; (b) formoterol, o una sal del mismo o un solvato de dicha sal, con una dosificación dentro del rango entre 1 y 25 mg por accionamiento; (c) un propelente que consiste en un HFA; (d) un co-solvente; (e) una cantidad útil como estabilizante de un ácido mineral, donde dicha composición está contenida en un envase de aerosol provisto de una válvula dosificadora que tiene por lo menos una junta de caucho butílico. Reivindicación 2: Una composición farmacéutica en solución para aerosol de acuerdo con la reivindicación 1 caracterizada porque la cantidad del producto de degradación N-(3-bromo)-[2-hidroxi-5-[1-hidroxi-2-[1-(4-metoxifenil)propan-2-ilamino]etil]fenil]formamida es menor al 0,10% peso en peso con respecto al contenido teórico de fumarato de formoterol de 6 mg/accionamiento, cuando se almacena en condiciones de envejecimiento acelerado a 25ºC y 60% de humedad relativa (RH) durante por lo menos 6 meses. Reivindicación 3: Una composición farmacéutica en solución para aerosol de acuerdo con la reivindicación 1 ó 2 caracterizada porque la cantidad de ácido mineral útil como estabilizante es una cantidad de ácido equivalente a ácido clorhídrico 1M dentro del rango entre 0,15 y 0,28 mg/ml. Reivindicación 9: Una composición farmacéutica en solución para aerosol de acuerdo con la reivindicación 8 caracterizada porque el corticoesteroide para inhalación se selecciona entre el grupo de: dipropionato de beclometasona, budesonida o su epímero 22R-, ciclesonida, flunisolida, propionato de fluticasona, furoato de fluticasona, furoato de mometasona, butixooort, triamcinolona acetonida, triamcinolona, metilprednisolona, prednisona, loteprednol y rofleponida. Reivindicación 14: Un envase de aerosol provisto de una válvula dosificadora que tiene por lo menos una junta de caucho butílico para utilizar con una composición farmacéutica en solución para aerosol para utilizar en un inhalador presurizado de dosis medida caracterizada porque comprende: (a) bromuro de glicopirronio con una dosificación dentro del rango entre 5 y 26 mg por accionamiento; (b) formoterol, o una sal del mismo o un solvato de dicha sal, con una dosificación dentro del rango entre 1 y 25 mg por accionamiento; (c) un propelente que consiste en un HFA, (d) un co-solvente; (e) una cantidad útil como estabilizante de un ácido mineral, y, opcionalmente, (f) un corticoesteroide para inhalación. Reivindicación 15: Un método para reducir la cantidad del producto de degradación N-(3-bromo)-[2-hidroxi-5-[1-hidroxi-2-[1-(4-metoxifenil)propan-2-ilamino]etil]fenil]formamida (DP3) durante la vida de estante de una composición farmacéutica en solución para aerosol para utilizar en un inhalador presurizado de dosis medida que comprende: (a) bromuro de glicopirronio con una dosificación dentro del rango entre 5 y 26 mg por accionamiento; (b) formoterol, o una sal del mismo o un solvato de dicha sal, con una dosificación dentro del rango entre 1 y 25 mg por accionamiento; (c) un propelente que consiste en un HFA,(d) un co-solvente; (e) una cantidad útil como estabilizante de un ácido mineral, y, opcionalmente, (f) un corticoesteroide para inhalación caracterizado porque dicho método comprende envasar la anterior composición en un envase de aerosol provisto de una válvula dosificadora que tiene por lo menos una junta de caucho butílico.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13199783 | 2013-12-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR098983A1 true AR098983A1 (es) | 2016-06-22 |
Family
ID=49886776
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140104939A AR098983A1 (es) | 2013-12-30 | 2014-12-29 | Composición combinada de bromuro de glicopirronio y formoterol en solución estable presurizada para aerosol |
| ARP230102184A AR130238A2 (es) | 2013-12-30 | 2023-08-17 | Método para reducir la cantidad del producto de degradación dp3 durante la vida de estante de una composición farmacéutica en solución para aerosol y uso de un envase de aerosol asociado |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP230102184A AR130238A2 (es) | 2013-12-30 | 2023-08-17 | Método para reducir la cantidad del producto de degradación dp3 durante la vida de estante de una composición farmacéutica en solución para aerosol y uso de un envase de aerosol asociado |
Country Status (36)
| Country | Link |
|---|---|
| US (3) | US20150182459A1 (es) |
| EP (1) | EP3096737B1 (es) |
| JP (2) | JP6534397B2 (es) |
| KR (1) | KR101865131B1 (es) |
| CN (2) | CN113143894A (es) |
| AR (2) | AR098983A1 (es) |
| AU (1) | AU2014375300B2 (es) |
| BR (1) | BR112016014586A2 (es) |
| CA (1) | CA2935302C (es) |
| CL (1) | CL2016001652A1 (es) |
| CY (1) | CY1120205T1 (es) |
| DK (1) | DK3096737T3 (es) |
| EA (1) | EA033228B1 (es) |
| ES (1) | ES2666905T4 (es) |
| GE (1) | GEP20186870B (es) |
| HR (1) | HRP20180944T1 (es) |
| HU (1) | HUE039359T2 (es) |
| IL (1) | IL246502B (es) |
| LT (1) | LT3096737T (es) |
| MA (1) | MA39154A1 (es) |
| ME (1) | ME03076B (es) |
| MX (1) | MX368834B (es) |
| MY (1) | MY176191A (es) |
| NO (1) | NO3096737T3 (es) |
| PE (1) | PE20161132A1 (es) |
| PH (1) | PH12016501269B1 (es) |
| PL (1) | PL3096737T3 (es) |
| PT (1) | PT3096737T (es) |
| RS (1) | RS57269B1 (es) |
| SA (1) | SA516371428B1 (es) |
| SG (1) | SG11201605309UA (es) |
| SI (1) | SI3096737T1 (es) |
| TN (1) | TN2016000262A1 (es) |
| TR (1) | TR201809356T4 (es) |
| UA (1) | UA117846C2 (es) |
| WO (1) | WO2015101575A1 (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GEP20166479B (en) | 2009-12-23 | 2016-05-25 | Chiesi Farma Spa | Aerosol formulation for copd |
| BR112012015334A2 (pt) * | 2009-12-23 | 2016-03-15 | Chiesi Farma Spa | terapia combinada para doença pulmonar obstrutiva crônica |
| WO2011076843A2 (en) | 2009-12-23 | 2011-06-30 | Chiesi Farmaceutici S.P.A. | Combination therapy for copd |
| MA39154A1 (fr) * | 2013-12-30 | 2017-08-31 | Chiesi Farm Spa | Composition stable pressurisée de solution pour aérosol d'une combinaison de bromure de glycopyrronium et de formotérol |
| BR112016014583B1 (pt) * | 2013-12-30 | 2022-12-20 | Chiesi Farmaceutici S.P.A | Composição de solução farmacêutica em aerossol, inalador pressurizado de dose calibrada e uso da dita composição |
| GB201520862D0 (en) * | 2015-11-25 | 2016-01-13 | Jagotec Ag | Pharmaceutical composition |
| TW201735914A (zh) * | 2015-12-22 | 2017-10-16 | 阿斯特捷利康公司 | 用於治療慢性阻塞性肺疾病之醫藥組成物 |
| US10098837B2 (en) * | 2016-07-28 | 2018-10-16 | Chiesi Farmaceutici S.P.A. | Combination therapy for COPD |
| AU2017328907B2 (en) | 2016-09-19 | 2020-04-09 | Mexichem Fluor S.A. De C.V. | Pharmaceutical composition |
| US20220040086A1 (en) * | 2018-10-01 | 2022-02-10 | Kindeva Drug Delivery L.P. | Formulation and aerosol canisters, inhalers, and the like containing the formulation |
| US20220362225A1 (en) * | 2019-07-12 | 2022-11-17 | Kindeva Drug Delivery L.P. | Aerosol formulation, canister, and inhaler containing the formulation, and method of use |
| WO2021033081A1 (en) * | 2019-08-16 | 2021-02-25 | Glenmark Pharmaceutical Limited | Stable aerosol composition for inhalation comprising glycopyrronium, formoterol and corticosteroid |
| CN112438966B (zh) * | 2019-08-30 | 2022-08-26 | 四川普锐特药业有限公司 | 一种医用定量吸入气雾剂 |
| AU2019477296A1 (en) | 2019-12-02 | 2022-04-14 | Chiesi Farmaceutici S.P.A. | Stainles steel can for pressurised metered dose inhalers |
| US20210205223A1 (en) * | 2020-01-04 | 2021-07-08 | Cai Gu Huang | Propellant-free formulation for inhalation |
| GEP20247594B (en) * | 2020-01-28 | 2024-02-12 | Chiesi Farm Spa | Pressurised metered dose inhalers comprising a buffered pharmaceutical formulation |
| WO2021165348A1 (en) * | 2020-02-20 | 2021-08-26 | Chiesi Farmaceutici S.P.A. | Pressurised metered dose inhalers comprising a buffered pharmaceutical formulation |
| MX2023001201A (es) | 2020-07-31 | 2023-05-03 | Chemo Res S L | Terapia combinada para la administracion por inhalacion. |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060171899A1 (en) * | 1998-12-10 | 2006-08-03 | Akwete Adjei | Water-stabilized aerosol formulation system and method of making |
| HRP20021025B1 (hr) * | 2000-05-22 | 2013-11-22 | Chiesi Farmaceutici S.P.A. | Formulacije stabilnih farmaceutskih otopina za inhalatore s odmjerenom dozom pod tlakom |
| US6750210B2 (en) * | 2000-08-05 | 2004-06-15 | Smithkline Beecham Corporation | Formulation containing novel anti-inflammatory androstane derivative |
| US20040126325A1 (en) * | 2002-03-12 | 2004-07-01 | David Lewis | Medicinal aerosol solution formulation products with improved chemical stability |
| GB0315791D0 (en) * | 2003-07-07 | 2003-08-13 | 3M Innovative Properties Co | Two component molded valve stems |
| HRP20080439T3 (hr) * | 2004-02-06 | 2008-10-31 | Meda Pharma Gmbh & Co. Kg | Nova kombinacija antikolinergika i beta mimetika za liječenje respiratornih bolesti |
| EP1595531A1 (en) * | 2004-05-13 | 2005-11-16 | CHIESI FARMACEUTICI S.p.A. | Stable pharmaceutical solution formulations for pressurized metered dose inhalers |
| AU2005245248A1 (en) | 2004-05-13 | 2005-12-01 | Chiesi Farmaceutici S.P.A. | Medicinal aerosol formulation products with improved chemical stability |
| GB0613161D0 (en) * | 2006-06-30 | 2006-08-09 | Novartis Ag | Organic Compounds |
| EP2201934A1 (en) * | 2008-12-23 | 2010-06-30 | CHIESI FARMACEUTICI S.p.A. | Tiotropium aerosol formulation products with improved chemical stability |
| US20110132355A1 (en) * | 2009-06-09 | 2011-06-09 | William Gerhart | Treatment of chronic obstructive pulmonary disease with nebulized beta 2-agonist or combined nebulized beta 2-agonist and anticholinergic administration |
| ES2467928T3 (es) | 2009-12-23 | 2014-06-13 | Chiesi Farmaceutici S.P.A. | Formulación en aerosol para EPOC |
| BR112012015334A2 (pt) | 2009-12-23 | 2016-03-15 | Chiesi Farma Spa | terapia combinada para doença pulmonar obstrutiva crônica |
| GEP20166479B (en) * | 2009-12-23 | 2016-05-25 | Chiesi Farma Spa | Aerosol formulation for copd |
| WO2011076843A2 (en) * | 2009-12-23 | 2011-06-30 | Chiesi Farmaceutici S.P.A. | Combination therapy for copd |
| AU2011368334A1 (en) * | 2011-05-17 | 2013-11-21 | Pearl Therapeutics, Inc. | Compositions, methods & systems for respiratory delivery of two or more active agents |
| BR112016014583B1 (pt) * | 2013-12-30 | 2022-12-20 | Chiesi Farmaceutici S.P.A | Composição de solução farmacêutica em aerossol, inalador pressurizado de dose calibrada e uso da dita composição |
| MA39154A1 (fr) * | 2013-12-30 | 2017-08-31 | Chiesi Farm Spa | Composition stable pressurisée de solution pour aérosol d'une combinaison de bromure de glycopyrronium et de formotérol |
-
2014
- 2014-12-23 MA MA39154A patent/MA39154A1/fr unknown
- 2014-12-23 SG SG11201605309UA patent/SG11201605309UA/en unknown
- 2014-12-23 EP EP14827449.1A patent/EP3096737B1/en active Active
- 2014-12-23 KR KR1020167020696A patent/KR101865131B1/ko active Active
- 2014-12-23 JP JP2016561078A patent/JP6534397B2/ja active Active
- 2014-12-23 TR TR2018/09356T patent/TR201809356T4/tr unknown
- 2014-12-23 MX MX2016008591A patent/MX368834B/es active IP Right Grant
- 2014-12-23 PE PE2016000969A patent/PE20161132A1/es unknown
- 2014-12-23 TN TN2016000262A patent/TN2016000262A1/en unknown
- 2014-12-23 RS RS20180635A patent/RS57269B1/sr unknown
- 2014-12-23 DK DK14827449.1T patent/DK3096737T3/en active
- 2014-12-23 MY MYPI2016001208A patent/MY176191A/en unknown
- 2014-12-23 UA UAA201606911A patent/UA117846C2/uk unknown
- 2014-12-23 PT PT148274491T patent/PT3096737T/pt unknown
- 2014-12-23 CN CN202110424305.5A patent/CN113143894A/zh active Pending
- 2014-12-23 CN CN201480071531.8A patent/CN105848642A/zh active Pending
- 2014-12-23 GE GEAP201414192A patent/GEP20186870B/en unknown
- 2014-12-23 EA EA201691127A patent/EA033228B1/ru unknown
- 2014-12-23 AU AU2014375300A patent/AU2014375300B2/en active Active
- 2014-12-23 CA CA2935302A patent/CA2935302C/en active Active
- 2014-12-23 HU HUE14827449A patent/HUE039359T2/hu unknown
- 2014-12-23 ME MEP-2018-149A patent/ME03076B/me unknown
- 2014-12-23 NO NO14827449A patent/NO3096737T3/no unknown
- 2014-12-23 HR HRP20180944TT patent/HRP20180944T1/hr unknown
- 2014-12-23 SI SI201430734T patent/SI3096737T1/en unknown
- 2014-12-23 WO PCT/EP2014/079258 patent/WO2015101575A1/en not_active Ceased
- 2014-12-23 LT LTEP14827449.1T patent/LT3096737T/lt unknown
- 2014-12-23 BR BR112016014586A patent/BR112016014586A2/pt not_active Application Discontinuation
- 2014-12-23 PL PL14827449T patent/PL3096737T3/pl unknown
- 2014-12-23 ES ES14827449.1T patent/ES2666905T4/es active Active
- 2014-12-29 AR ARP140104939A patent/AR098983A1/es not_active Application Discontinuation
- 2014-12-30 US US14/585,366 patent/US20150182459A1/en not_active Abandoned
-
2016
- 2016-06-28 PH PH12016501269A patent/PH12016501269B1/en unknown
- 2016-06-28 IL IL246502A patent/IL246502B/en active IP Right Grant
- 2016-06-28 CL CL2016001652A patent/CL2016001652A1/es unknown
- 2016-06-28 SA SA516371428A patent/SA516371428B1/ar unknown
- 2016-06-29 US US15/196,253 patent/US10617669B2/en active Active
- 2016-12-15 US US15/379,924 patent/US10596149B2/en active Active
-
2018
- 2018-05-15 CY CY20181100498T patent/CY1120205T1/el unknown
-
2019
- 2019-03-20 JP JP2019053624A patent/JP6826145B2/ja active Active
-
2023
- 2023-08-17 AR ARP230102184A patent/AR130238A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR098983A1 (es) | Composición combinada de bromuro de glicopirronio y formoterol en solución estable presurizada para aerosol | |
| AR098982A1 (es) | Composición combinada de bromuro de glicopirronio y formoterol en solución estable presurizada para aerosol | |
| MX2021009476A (es) | Composiciones farmacéuticas que comprenden sales de glicopirrolato y 1,1-difluoroetano. | |
| AR079726A1 (es) | Terapia combinada para enfermedad pulmonar obstructiva cronica (epoc) . composicion farmaceutica.frasco de aerosol. metodo.conjunto de componentes | |
| MX340924B (es) | Composiciones farmaceuticas. | |
| CL2022002235A1 (es) | Inhaladores dosificadores presurizados que comprenden una formulación farmacéutica amortiguada | |
| AR081540A1 (es) | Proceso para proveer particulas con cargas electroestaticas reducidas | |
| MX2024002495A (es) | Inhaladores de dosis medida y composiciones en suspension. | |
| NZ600789A (en) | Aerosol formulation for copd | |
| CO2022012207A2 (es) | Inhaladores de dosis medida presurizada que comprenden una formulación farmacéutica amortiguada | |
| AR123674A2 (es) | Composición farmacéutica en aerosol de formoterol y dipropionato de beclometasona | |
| NZ786610A (en) | Stainless steel can for pressurised metered dose inhalers | |
| TH171992A (th) | องค์ประกอบสารละลายชนิดละอองลอยแบบอัดความดันที่เสถียรของการรวมกันของ ไกลโคไพร์โรเนียมโบรไมด์ และฟอร์โมเทอรอล | |
| NZ786610B2 (en) | Stainless steel can for pressurised metered dose inhalers | |
| TH171993A (th) | องค์ประกอบสารละลายชนิดละอองลอยแบบอัดความดันที่เสถียรของการรวมกันของ ไกลโคไพร์โรเนียมโบรไมด์ และฟอร์โมเทอรอล | |
| AR085443A1 (es) | Formulaciones medicinales en aerosol que no dañan la capa de ozono y con bajo efecto invernadero | |
| AR100619A1 (es) | COMPOSICIÓN FARMACÉUTICA QUE COMBINA INHIBIDORES DE FOSFOINOSÍTIDO 3-QUINASA d Y CORTICOESTEROIDES PARA EL TRATAMIENTO DE ENFERMEDADES CUTÁNEAS INMUNOAMPOLLOSAS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |